Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 15/20 | 0.50 |
| ▸ | PPARG | P37231 | 13/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 6/20 | 0.47 |
| ▸ | PLAU | P00749 | 2/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | PLAT | P00750 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14122371 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2PPARAPPARGPTGDR2PPARD | |
| SCHEMBL13433919 | 0.86 | SMN1; SMN2 (0.56) | SMN1; SMN2PPARAPPARGPTGDR2PPARD | |
| SCHEMBL13384143 | 0.85 | L3MBTL1 (0.48) | SMN1; SMN2PPARAPPARGPTGDR2 | |
| SCHEMBL2897929 | 0.85 | L3MBTL1 (0.48) | SMN1; SMN2PPARAPPARGPTGDR2 | |
| SCHEMBL14122075 | 0.85 | ALDH1A1 (0.44) | SMN1; SMN2 | |
| SCHEMBL14121943 | 0.85 | ALDH1A1 (0.44) | SMN1; SMN2 | |
| SCHEMBL14121944 | 0.85 | ALDH1A1 (0.44) | SMN1; SMN2 | |
| SCHEMBL14266882 | 0.85 | L3MBTL1 (0.48) | SMN1; SMN2PPARAPPARGPTGDR2 | |
| SCHEMBL200619 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2PPARAPPARG | |
| SCHEMBL1125437 | 0.81 | CYP2C9 (0.50) | PPARAPPARGPTGDR2PPARDPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537078-B1 | INDOLES HAVING ANTI-DIABETIC ACTIVITY | MERCK SHARP & DOHME (US) | 2010-04-14 | — | — | EP | disclosed |
| US-7345085-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070161689-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2007-07-12 | — | — | US | disclosed |
| US-7186746-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050277685-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2005-12-15 | — | — | US | disclosed |
| EP-1537078-A1 | INDOLES HAVING ANTI-DIABETIC ACTIVITY | Merck & Co., Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020408-A1 | INDOLES HAVING ANTI-DIABETIC ACTIVITY | MERCK & CO., INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004020409-A1 | INDOLES HAVING ANTI-DIABETIC ACTIVITY | MERCK & CO., INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277685-A1 | Indoles having anti-diabetic activity | GPR119, PPARA, PPARG | SMN1; SMN2 4871/4885PPARA 2/4885PPARG 3/4885 |
| US-20070161689-A1 | Indoles having anti-diabetic activity | GPR119, PPARA, PPARG | SMN1; SMN2 4871/4885PPARA 2/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.